Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01186692 · ClinicalTrials.gov registry record · NA

Melody® Transcatheter Pulmonary Valve Post-Approval Study

A NA study, sponsored by Medtronic Cardiovascular.

Completed
Registry status
NA
Development phase
131
Enrollment target

NCT01186692: Completed NA study, sponsored by Medtronic Cardiovascular.

NCT01186692 is a NA study that has completed, run by Medtronic Cardiovascular. The registered enrollment target is 131 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (91% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01186692, a NA study, has completed, sponsored by Medtronic Cardiovascular.

COMPLETED
Registry status
NA
Development phase
131 participants
Enrollment target

Study Summary

The purpose of this study is to confirm the short-term hemodynamic effectiveness results achieved by real-world providers are equivalent to the historical control established in the IDE study.

Primary Outcome

Acceptable TPV hemodynamic function at six months after successful TPV implantation is determined as a composite of the following: * Mean RVOT gradient is less than or equal to 30 mmHg as measured by CW Doppler, and * Severity of pulmonary regurgitation is less than moderate by Doppler echocardiography, and * Free from RVOT conduit reoperation or catheter re-intervention at six months after TPV implantation. The endpoint is defined as the percentage of subjects with acceptable TPV hemodynamic

Interventions

  • DEVICE Melody® Transcatheter Pulmonary Valve

Trial Details

FieldValue
Enrollment Target 131 participants
Start Date 2010-07
Est. Completion 2017-10
Phase NA
Medtronic Cardiovascular

44 total trials

What the finished NCT01186692 record still lists

NCT01186692 is an interventional study that assigns participants to a tested intervention. The registered 131 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (91% lower).

The record links to 0 conditions, and to 1 intervention - of which Melody® Transcatheter Pulmonary Valve is the first listed.

NCT01186692 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01186692 about?

NCT01186692 is a clinical study titled "Melody® Transcatheter Pulmonary Valve Post-Approval Study". The purpose of this study is to confirm the short-term hemodynamic effectiveness results achieved by real-world providers are equivalent to the historical control established in the IDE study.

What is the current status of trial NCT01186692?

This trial is currently completed. It is a NA study. The enrollment target is 131 participants. The study started on 2010-07. Estimated completion is 2017-10.

What interventions are being tested in trial NCT01186692?

The interventions under investigation include: Melody® Transcatheter Pulmonary Valve (DEVICE).

Who is sponsoring clinical trial NCT01186692?

This trial is sponsored by Medtronic Cardiovascular, which has 44 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01186692's enrollment target sits among peer trials

131 732nd of 2000 higher than 1,268 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03051464 · 131 participants · Phase 2

    No Surgery Trial / Two Dose-escalation Strategies

  • NCT04301843 · 131 participants · Phase 2

    Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma

  • NCT04748549 · 131 participants · NA

    Intraoperative VR for Older Patients Undergoing TKA

  • NCT05951179 · 131 participants · Phase 2

    Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01186692, the US trial registry maintained by the National Library of Medicine. NCT01186692 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.